Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADLSOTCMKTS:AVXTOTCMKTS:CRXMOTCMKTS:CRXTQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADLSAdvanced Life Sciences$0.01+9,900.0%$0.01$0.00▼$0.01N/AN/A4,868 shs1,000 shsAVXTAVAX Technologies$0.00$0.00▼$0.00N/AN/AN/AN/ACRXMCardium Therapeutics$0.00$0.00▼$0.00N/AN/AN/AN/ACRXTQClarus Therapeutics$0.00$0.00$0.00▼$3.94N/AN/AN/AN/A12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADLSAdvanced Life Sciences0.00%0.00%0.00%0.00%0.00%AVXTAVAX Technologies0.00%0.00%0.00%0.00%0.00%CRXMCardium Therapeutics0.00%0.00%0.00%0.00%0.00%CRXTQClarus Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADLSAdvanced Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AAVXTAVAX TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACRXMCardium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACRXTQClarus TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADLSAdvanced Life Sciences 0.00N/AN/AN/AAVXTAVAX Technologies 0.00N/AN/AN/ACRXMCardium Therapeutics 0.00N/AN/AN/ACRXTQClarus Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADLSAdvanced Life SciencesN/AN/AN/AN/AN/AN/AAVXTAVAX TechnologiesN/AN/AN/AN/AN/AN/ACRXMCardium TherapeuticsN/AN/AN/AN/AN/AN/ACRXTQClarus TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADLSAdvanced Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/AAVXTAVAX TechnologiesN/AN/A0.00N/AN/AN/AN/AN/AN/ACRXMCardium TherapeuticsN/AN/A0.00N/AN/AN/AN/AN/AN/ACRXTQClarus TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADLSAdvanced Life SciencesN/AN/AN/AN/AN/AAVXTAVAX TechnologiesN/AN/AN/AN/AN/ACRXMCardium TherapeuticsN/AN/AN/AN/AN/ACRXTQClarus TherapeuticsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADLSAdvanced Life SciencesN/AAVXTAVAX TechnologiesN/ACRXMCardium TherapeuticsN/ACRXTQClarus TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipADLSAdvanced Life Sciences12.00%AVXTAVAX Technologies6.00%CRXMCardium Therapeutics49.80%CRXTQClarus Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADLSAdvanced Life SciencesN/AN/AN/ANot OptionableAVXTAVAX Technologies9N/AN/ANot OptionableCRXMCardium Therapeutics3N/AN/ANot OptionableCRXTQClarus Therapeutics2N/AN/ANot OptionableCRXM, ADLS, AVXT, and CRXTQ HeadlinesRecent News About These CompaniesClarus Stock (NASDAQ:CLAR), Analyst Ratings, Price Targets, PredictionsJanuary 5, 2024 | benzinga.comClarus SQ 8C GC/Mass Spectrometer from PerkinElmerMay 11, 2023 | news-medical.netNClarus ¢erdot; Horse ProfileMay 3, 2023 | punters.com.auPClarus Therapeutics Hldgs Stock (OTC:CRXWQ), Earnings Estimates, EPS, and RevenueOctober 12, 2022 | benzinga.comClarus Therapeutics Hldgs Stock (OTC:CRXWQ), Analyst Ratings, Price Targets, PredictionsOctober 12, 2022 | benzinga.comClarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using ...September 6, 2022 | elpasoinc.comClarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy CodeSeptember 5, 2022 | finance.yahoo.comClarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering ...July 30, 2022 | eagletribune.comEClarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)July 28, 2022 | finance.yahoo.comClarus Therapeutics Holdings Inc.July 19, 2022 | wsj.comClarus Therapeutics Holdings, Inc. (CRXT)July 12, 2022 | finance.yahoo.comClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual MeetingJune 9, 2022 | finance.yahoo.comClarus Therapeutics Holdings Inc. [CRXT] Is Currently 19.76 above its 200 Period Moving Avg: What Does This Mean?June 3, 2022 | dbtnews.comDMarket cap of Clarus Therapeutics Holdings Inc. [CRXT] reaches 22.96M – now what?May 24, 2022 | dbtnews.comDClarus' oral testosterone product Jatenzo gets patent nodMay 18, 2022 | seekingalpha.comClarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)May 18, 2022 | finance.yahoo.comMarket cap of Clarus Therapeutics Holdings Inc. [CRXT] reaches 12.67M – now what?May 17, 2022 | dbtnews.comDClarus Therapeutics Holdings, Inc. (CRXT) CEO Bob Dudley on Q1 2022 Results - Earnings Call TranscriptMay 16, 2022 | seekingalpha.comClarus Therapeutics Misses Q1 EPS by 21cMay 16, 2022 | investing.comClarus Therapeutics Reports First Quarter 2022 Financial and Operating ResultsMay 16, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRXM, ADLS, AVXT, and CRXTQ Company DescriptionsAdvanced Life Sciences OTCMKTS:ADLS$0.01 +0.01 (+9,900.00%) As of 08/16/2019Advanced Life Sciences Inc. is a biopharmaceutical company and its lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of life-threatening infections including community-acquired bacterial pneumonia and biodefense pathogens including anthrax, plague and tularemia. The Company has developed a promising pipeline of clinical and preclinical product candidates from both in-licensing efforts and the discovery programs in the areas of infectious disease, oncology, and respiratory disease. It develops ALS-357, a natural product in preclinical studies has demonstrated specific anti-tumor activity against malignant melanoma. It has a unique mechanism of action that disrupts mitochondrial membrane function and is associated with the intrinsic, mitochondria-mediated pathway of apoptosis. The Company develops ALS-886, a novel treatment intended to reduce and prevent the tissue damage associated with diseases such as Adult Respiratory Distress Syndrome (ARDS).AVAX Technologies OTCMKTS:AVXTAVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.Cardium Therapeutics OTCMKTS:CRXMGene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.Clarus Therapeutics OTCMKTS:CRXTQ$0.0010 0.00 (0.00%) As of 03/6/2023Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
